PENNSAUKEN, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of solutions designed to enhance the operational performance of its customers through the deployment of advanced engineering, specialty healthcare, and information technology services, today announced financial results for the fourteen and fifty-three weeks ended January 3, 2026.
RCM Technologies reported revenue of $86.5 million for the fourteen weeks ended January 3, 2026 (the current quarter), an increase of 12.4% compared to $76.9 million for the thirteen weeks ended December 28, 2024 (the comparable prior quarter). Gross profit was $24.3 million for the current quarter, a 12.6% increase compared to $21.6 million for the comparable prior quarter. The Company reported GAAP net income of $6.1 million, or $0.80 per diluted share, for the current quarter, compared with $2.9 million, or $0.37 per diluted share, for the comparable prior quarter. The Company reported adjusted EBITDA (non-GAAP) of $9.3 million for the current quarter, as compared to $6.3 million for the comparable prior quarter, an increase of 49.0%. The Company experienced $0.77 of adjusted net income per diluted share (non-GAAP) for the current quarter as compared to $0.49 for the comparable prior quarter.
RCM Technologies reported revenue of $319.4 million for the fifty-three weeks ended January 3, 2026 (the current year), an increase of 14.7% compared to $278.4 million for the fifty-two weeks ended December 28, 2024 (the comparable prior year). Gross profit was $87.9 million for the current year, a 10.2% increase compared to $79.8 million for the comparable prior year. The Company reported GAAP net income of $16.3 million, or $2.14 per diluted share, for the current year compared to $13.3 million, or $1.68 per diluted share, for the comparable prior year. The Company reported adjusted EBITDA (non-GAAP) of $30.7 million for the current year as compared to $25.9 million for the comparable prior year, an increase of 18.9%. The Company reported $2.50 of adjusted net income per diluted share (non-GAAP) for the current year as compared to $2.03 for the comparable prior year.
The Company will not be holding a conference call to discuss these results. Additional information can be found in the Company’s Form 10-K.
About RCM
RCM Technologies (NasdaqGM: RCMT) is a business and technology solutions provider with world-class talent in key market segments. We help design, build, and enable the Industries of Tomorrow, Today. Operating at the intersection of resources, critical infrastructure and modernization of industries, RCM is a provider of services in Healthcare, Engineering, Aerospace & Defense, Process & Industrial, Life Sciences and Data & Solutions. www.rcmt.com.
The statements contained in this release that are not purely historical are forward-looking statements within the Private Securities Litigation Reform Act of 1995. They are subject to various risks, uncertainties, and other factors that could cause the Company’s actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “believe,” “plan,” “seek,” “could,” “can,” “should,” “are confident” or similar expressions. In addition, statements that are not historical should also be considered forward-looking statements. These statements are based on assumptions that we have made in light of our experience in the industry, and our perceptions of historical trends, current conditions, expected future developments, and other factors we believe are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to demand for the Company’s services, expectations regarding our future revenues and other financial results, such as cash flows, our pipeline, and potential project wins, and our expectations for investment and growth in our business. Such statements are based on current expectations that involve several known and unknown risks, uncertainties, and other factors, which may cause actual events to be materially different from those expressed or implied by such forward-looking statements. Risk, uncertainties, and other factors may emerge from time to time that could cause the Company’s actual results to differ from those indicated by the forward-looking statements. Investors are directed to consider such risks, uncertainties, and other factors described in documents filed by the Company with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company assumes no obligation (and expressly disclaims any such obligation) to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.
Tables to Follow
Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share amounts) | ||||
| Fourteen and Thirteen Weeks Ended | ||||
2026 |
2024 |
|||
| Revenue | ||||
| Cost of services | 62,198 | 55,343 | ||
| Gross profit | 24,278 | 21,569 | ||
| Selling, general and administrative | 15,753 | 16,025 | ||
| Depreciation and amortization of property and equipment | 554 | 407 | ||
| Impairment of intangible assets | - | 547 | ||
| Potential stock issuance and financing transactions | - | 64 | ||
| Remeasurement of contingent consideration | - | (1,759 | ) | |
| Operating income | 7,971 | 6,285 | ||
| Other expense, net | 780 | 516 | ||
| Income before income taxes | 7,191 | 5,769 | ||
| Income tax expense | 1,087 | 2,902 | ||
| Net income | ||||
| Diluted net earnings per share data | ||||
| Diluted weighted average shares outstanding | 7,587,448 | 7,733,142 | ||
| Fifty-Three and Fifty-Two Weeks Ended | ||||
2026 |
2024 |
|||
| Revenue | ||||
| Cost of services | 231,461 | 198,602 | ||
| Gross profit | 87,943 | 79,778 | ||
| Selling, general and administrative | 60,932 | 56,787 | ||
| Depreciation and amortization of property and equipment | 1,918 | 1,419 | ||
| Amortization of acquired intangible assets | - | 136 | ||
| Impairment of intangible assets | - | 547 | ||
| Potential stock issuance and financing transactions | - | 323 | ||
| Remeasurement of contingent consideration | - | (1,759 | ) | |
| Operating income | 25,093 | 22,325 | ||
| Other expense, net | 3,021 | 2,135 | ||
| Income before income taxes | 22,072 | 20,190 | ||
| Income tax expense | 5,738 | 6,863 | ||
| Net income | ||||
| Diluted net earnings per share data | ||||
| Diluted weighted average shares outstanding | 7,635,740 | 7,939,381 | ||
Supplemental Operating Results on a Non-GAAP Basis (Unaudited) (In thousands) |
The following non-GAAP measures, which adjust for the categories of expenses described below, are non-GAAP financial measures. Our management believes that these non-GAAP financial measures (“Adjusted operating income,” “EBITDA,” “Adjusted EBITDA,” “Adjusted net income” and “Adjusted diluted net earnings per share”) are useful information for investors, shareholders, and other stakeholders of our Company in gauging our results of operations on an ongoing basis and to enhance investors’ overall understanding of our current financial performance and period-to-period comparisons. Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income, and Adjusted diluted net earnings per share should not be considered alternatives to operating income or net income, as the case may be, as an indicator of performance. In addition, Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income, and Adjusted diluted net earnings per share do not take into account changes in certain assets and liabilities and interest and income taxes that can affect cash flows. We do not intend the presentation of these non-GAAP measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP. These non-GAAP measures should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP.
The following unaudited table presents the Company’s GAAP operating income and GAAP net income and the corresponding adjustments used to calculate Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income, and Adjusted diluted net earnings per share for the fourteen and fifty-three weeks ended January 3, 2026, and the thirteen and fifty-two weeks ended December 28, 2024.
| Fourteen and Thirteen Weeks Ended |
Fifty-Three and Fifty-Two Weeks Ended |
|||||||
2026 |
2024 |
2026 |
2024 |
|||||
| GAAP operating income | ||||||||
| Adjustments | ||||||||
| Remeasurement of contingent consideration | - | (1,759 | ) | - | (1,759 | ) | ||
| Equity compensation | 793 | 710 | 3,732 | 2,864 | ||||
| Potential stock issuance and financing transaction | - | 64 | - | 323 | ||||
| Impairment of intangible assets | - | 547 | - | 547 | ||||
| Adjusted operating income (non-GAAP) | ||||||||
| GAAP net income | ||||||||
| Income tax expense | 1,087 | 2,902 | 5,738 | 6,863 | ||||
| Interest expense, net | 784 | 664 | 2,669 | 2,215 | ||||
| Depreciation of property and equipment | 554 | 407 | 1,918 | 1,419 | ||||
| Amortization of acquired intangible assets | - | - | - | 136 | ||||
| EBITDA (non-GAAP) | ||||||||
| Adjustments | ||||||||
| Remeasurement of contingent consideration | - | (1,759 | ) | - | (1,759 | ) | ||
| (Gain) loss on foreign currency transactions | (4 | ) | (148 | ) | 352 | (80 | ) | |
| Equity compensation | 793 | 710 | 3,732 | 2,864 | ||||
| Potential stock issuance and financing transaction | - | 64 | - | 323 | ||||
| Impairment of intangible assets | - | 547 | - | 547 | ||||
| Adjusted EBITDA (non-GAAP) | ||||||||
Supplemental Operating Results on a Non-GAAP Basis (Continued) (Unaudited) (In thousands, except per share amounts) | ||||||||||||
| Fourteen and Thirteen Weeks Ended | Fifty-Three and Fifty-Two Weeks Ended | |||||||||||
2026 |
2024 |
2026 |
2024 |
|||||||||
| GAAP net income | ||||||||||||
| Adjustments | ||||||||||||
| Remeasurement of contingent consideration | - | (1,759 | ) | - | (1,759 | ) | ||||||
| (Gain) loss on foreign currency transactions | (4 | ) | (148 | ) | 352 | (80 | ) | |||||
| Equity compensation | 793 | 710 | 3,732 | 2,864 | ||||||||
| Potential stock issuance and financing transaction | - | 64 | - | 323 | ||||||||
| Impairment of intangible assets | - | 547 | - | 547 | ||||||||
| Tax impact from normalized rate | (1,068 | ) | 1,503 | (1,324 | ) | 900 | ||||||
| Adjusted net income (non-GAAP) | ||||||||||||
| GAAP diluted net earnings per share | ||||||||||||
| Adjustments | ||||||||||||
| Remeasurement of contingent consideration | - | ( |
) | - | ( |
) | ||||||
| (Gain) loss on foreign currency transactions | ( |
) | ( |
) | ( |
) | ||||||
| Equity compensation | ||||||||||||
| Potential stock issuance and financing transaction | - | - | ||||||||||
| Impairment of intangible assets | - | - | ||||||||||
| Tax impact from normalized rate(a) | ( |
) | ( |
) | ( |
) | ||||||
| Adjusted diluted net earnings per share (non-GAAP) | ||||||||||||
| (a) | Amount reflects an adjustment to income tax expense applied to non-GAAP adjusted consolidated taxable income. The Company used an estimated effective income tax rate of 27.0% for both periods presented, approximating the Company’s federal |
Summary of Selected Income Statement Data (Unaudited) (In thousands) | ||||||||||||
| Fourteen Weeks Ended |
||||||||||||
| Specialty Health Care |
Engineering | Life Sciences, Data and Solutions |
Consolidated | |||||||||
| Revenue | ||||||||||||
| Cost of services | 34,067 | 22,608 | 5,523 | 62,198 | ||||||||
| Gross profit | ||||||||||||
| Gross profit margin | 29.0 | % | 25.6 | % | 31.6 | % | 28.1 | % | ||||
| Thirteen Weeks Ended |
||||||||||||
| Specialty Health Care |
Engineering | Life Sciences, Data and Solutions |
Consolidated | |||||||||
| Revenue | ||||||||||||
| Cost of services | 28,474 | 21,098 | 5,771 | 55,343 | ||||||||
| Gross profit | ||||||||||||
| Gross profit margin | 30.6 | % | 19.7 | % | 40.0 | % | 28.0 | % | ||||
| Fifty-Three Weeks Ended |
||||||||||||
| Specialty Health Care |
Engineering | Life Sciences, Data and Solutions |
Consolidated | |||||||||
| Revenue | ||||||||||||
| Cost of services | 116,702 | 93,104 | 21,655 | 231,461 | ||||||||
| Gross profit | ||||||||||||
| Gross profit margin | 28.9 | % | 22.7 | % | 37.8 | % | 27.5 | % | ||||
| Fifty-Two Weeks Ended |
||||||||||||
| Specialty Health Care |
Engineering | Life Sciences, Data and Solutions |
Consolidated | |||||||||
| Revenue | ||||||||||||
| Cost of services | 100,146 | 73,916 | 24,540 | 198,602 | ||||||||
| Gross profit | ||||||||||||
| Gross profit margin | 29.8 | % | 23.4 | % | 37.5 | % | 28.7 | % | ||||
| Fifty-Three and Fifty-Two Weeks Ended | ||||
2026 |
2024 |
|||
| Revenue | ||||
| Cost of services | 231,461 | 198,602 | ||
| Gross profit | 87,943 | 79,778 | ||
| Selling, general and administrative | 60,932 | 56,787 | ||
| Depreciation and amortization of property and equipment | 1,918 | 1,419 | ||
| Amortization of acquired intangible assets | - | 136 | ||
| Impairment of intangible assets | - | 547 | ||
| Potential stock issuance and financing transactions | - | 323 | ||
| Remeasurement of contingent consideration | - | (1,759 | ) | |
| Operating income | 25,093 | 22,325 | ||
| Other expense, net | 3,021 | 2,135 | ||
| Income before income taxes | 22,072 | 20,190 | ||
| Income tax expense | 5,738 | 6,863 | ||
| Net income | ||||
| Diluted net earnings per share data | ||||
| Diluted weighted average shares outstanding | 7,635,740 | 7,939,381 | ||
| Fifty-Three and Fifty-Two Weeks Ended | ||||
2026 |
2024 |
|||
| Revenue | ||||
| Cost of services | 231,461 | 198,602 | ||
| Gross profit | 87,943 | 79,778 | ||
| Selling, general and administrative | 60,932 | 56,787 | ||
| Depreciation and amortization of property and equipment | 1,918 | 1,419 | ||
| Amortization of acquired intangible assets | - | 136 | ||
| Impairment of intangible assets | - | 547 | ||
| Potential stock issuance and financing transactions | - | 323 | ||
| Remeasurement of contingent consideration | - | (1,759 | ) | |
| Operating income | 25,093 | 22,325 | ||
| Other expense, net | 3,021 | 2,135 | ||
| Income before income taxes | 22,072 | 20,190 | ||
| Income tax expense | 5,738 | 6,863 | ||
| Net income | ||||
| Diluted net earnings per share data | ||||
| Diluted weighted average shares outstanding | 7,635,740 | 7,939,381 | ||
| Fifty-Three and Fifty-Two Weeks Ended | ||||
2026 |
2024 |
|||
| Revenue | ||||
| Cost of services | 231,461 | 198,602 | ||
| Gross profit | 87,943 | 79,778 | ||
| Selling, general and administrative | 60,932 | 56,787 | ||
| Depreciation and amortization of property and equipment | 1,918 | 1,419 | ||
| Amortization of acquired intangible assets | - | 136 | ||
| Impairment of intangible assets | - | 547 | ||
| Potential stock issuance and financing transactions | - | 323 | ||
| Remeasurement of contingent consideration | - | (1,759 | ) | |
| Operating income | 25,093 | 22,325 | ||
| Other expense, net | 3,021 | 2,135 | ||
| Income before income taxes | 22,072 | 20,190 | ||
| Income tax expense | 5,738 | 6,863 | ||
| Net income | ||||
| Diluted net earnings per share data | ||||
| Diluted weighted average shares outstanding | 7,635,740 | 7,939,381 | ||
| Fifty-Three and Fifty-Two Weeks Ended | ||||
2026 |
2024 |
|||
| Revenue | ||||
| Cost of services | 231,461 | 198,602 | ||
| Gross profit | 87,943 | 79,778 | ||
| Selling, general and administrative | 60,932 | 56,787 | ||
| Depreciation and amortization of property and equipment | 1,918 | 1,419 | ||
| Amortization of acquired intangible assets | - | 136 | ||
| Impairment of intangible assets | - | 547 | ||
| Potential stock issuance and financing transactions | - | 323 | ||
| Remeasurement of contingent consideration | - | (1,759 | ) | |
| Operating income | 25,093 | 22,325 | ||
| Other expense, net | 3,021 | 2,135 | ||
| Income before income taxes | 22,072 | 20,190 | ||
| Income tax expense | 5,738 | 6,863 | ||
| Net income | ||||
| Diluted net earnings per share data | ||||
| Diluted weighted average shares outstanding | 7,635,740 | 7,939,381 | ||
| Fifty-Three and Fifty-Two Weeks Ended | ||||
2026 |
2024 |
|||
| Revenue | ||||
| Cost of services | 231,461 | 198,602 | ||
| Gross profit | 87,943 | 79,778 | ||
| Selling, general and administrative | 60,932 | 56,787 | ||
| Depreciation and amortization of property and equipment | 1,918 | 1,419 | ||
| Amortization of acquired intangible assets | - | 136 | ||
| Impairment of intangible assets | - | 547 | ||
| Potential stock issuance and financing transactions | - | 323 | ||
| Remeasurement of contingent consideration | - | (1,759 | ) | |
| Operating income | 25,093 | 22,325 | ||
| Other expense, net | 3,021 | 2,135 | ||
| Income before income taxes | 22,072 | 20,190 | ||
| Income tax expense | 5,738 | 6,863 | ||
| Net income | ||||
| Diluted net earnings per share data | ||||
| Diluted weighted average shares outstanding | 7,635,740 | 7,939,381 | ||
Image: https://www.globenewswire.com/newsroom/ti?nf=OTY4NDA2NiM3NTE5MDQ3IzIwMTg4OTA=
Image: https://ml.globenewswire.com/media/YmRjN2Q4NmYtNTFiZS00MTkwLThkNDItMWM4NzZlZjA0OWJiLTEwMzA0NjMtMjAyNi0wNC0wMy1lbg==/tiny/RCM-Technologies-Inc-.png Image: Primary Logo
Source: RCM Technologies, Inc.